Email updates

Keep up to date with the latest news and content from Critical Care and BioMed Central.

Highly Accessed Open Badges Commentary

Good-bye CRRT, here comes SLED? ... not so fast!

Michael Joannidis

Author Affiliations

Medical Intensive Care Unit, Department of General Internal Medicine I, Medical University Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria

Critical Care 2012, 16:167  doi:10.1186/cc11651

See related research by Schwenger et al.,

Published: 5 November 2012


In the continuing dispute about the superiority of either intermittent or continuous renal replacement therapy for the critically ill, hybrid methods such as sustained low-efficiency dialysis (SLED) combining the advantages of both modalities - that is, excellent hemodynamic stability and low costs - receive growing attention. The study by Schwenger and colleagues is the first randomized trial indicating that there may be no significant difference in survival at 90 days between patients treated with SLED as compared with those treated with continuous veno-venous hemofiltration.